SMARCA4 and non-small cell lung carcinoma: Liu et al.’s ICIs and non-ICIs treatment adenocarcinoma NSCLC analysis was associated with significantly worse OS or PFS across all four SMARCA4/KRAS co-mutated vs. SMARCA4 WT/KRAS-mutated cohorts [37].